Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 5
Submit an article Journal homepage
280
Views
21
CrossRef citations to date
0
Altmetric
Review

Evolution of treatments for patients with acute lung injury

Annette M EsperEmory University School of Medicine Pulmonary, Allergy and Critical Care, 49 Jesse Hill Junior Drive Southeast, Atlanta, GA 30303USATel: +1 404 616 0148; Fax: +1 404 616 8455;E-mail: [email protected]
&
Greg S MartinEmory University School of Medicine Pulmonary, Allergy and Critical Care, 49 Jesse Hill Junior Drive Southeast, Atlanta, GA 30303USATel: +1 404 616 0148; Fax: +1 404 616 8455;E-mail: [email protected]
Pages 633-645 | Published online: 31 May 2005

Bibliography

  • FRUTOS-VI VARF, NIN N, ESTEBAN A: Epidemiology of acute lung injury and acute respiratory distress syndrome. Curr. Opin. Grit. Care (2004) 10(1):1–6.
  • MILBERG JA, DAVIS DR, STEINBERG KP, HUDSON LD: Improved survival of patients with acute respiratory distress syndrome (ARDS). "AMA (1995) 273:306–309.
  • MARTIN GS, BERNARD GR: Airway and lung dysfunction in sepsis. Intensive Care Med. (2001) 27(Suppl.):563–579.
  • THE ARDS CLINICAL TRIALS NETWORK: Ventilation with lower tidal volume as compared with traditional tidal volume for acute lung injury and acute respiratory distress syndrome. N Engl. I Med. (2000) 342:1301–1308.
  • WARE LB, MATTHAY MA: The acute respiratory distress syndrome. N Engl. I Med. (2000) 342(18): 1334–1349.
  • THE ARDS CLINICAL TRIALS NETWORK: Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Grit. Care Med. (2002) 30(1):1–6.
  • •This study showed no evidence that lisofylline has beneficial effects in the treatment of ALT.
  • BERNARD GR, WHEELER AP, NAUM CC et al: A placebo-controlled randomized trial of IL-10 in acute lung injury. Chest (1999) 116(4):2605 (Abstract).
  • KID 01 Y, HINOHANA H, KUNIMOTO R et al.: Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Ariesth. Analg. (2004) 99:872–877.
  • LEE WL AND DOWNEY GP Leukocyte elastase: physiological functions and role in acute lung injury. Am. I Respir: Grit. Care Med. (2001)164:896–904.
  • ZEIHER BL, ARTIGAS A, VINCENT JL et atNeutrophil elastase inhibition in acute lung injury: results of the Strive study. Grit. Care Med. (2004) 32(8):1695–702.
  • KADOI Y, HINOHARA H, KUNIMOTO F et al: Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth. Anal. (2004) 99:872–7.
  • DELACOURT C, HERIGAULT S, DELCLAUX C et al: Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir: Cell Mol Biol. (2002) 26:290–297.
  • HONORE S, ATTALAH, HL, AZOULAY E et atBeneficial effect of an inhibitor of leukocyte elastase (EPI-HNE-4) in presence of repeated lung injuries. Shock (2004) 22(2):131–136.
  • NAKAMU T, OGAMI Y: Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury induced by the intratracheal instillation of endotoxin in piglets. Biuol. Neonate (2001) 80(2):163–168.
  • BERNARD G, WHEELER A, ARONS M et al: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest (1997) 112:164–172.
  • •This article reports that glutathione stores can be repleted using NAC.
  • SCHUSTER DP, METZLER M, OPA S et al.: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med. (2003) 31(6):1612–1619.
  • OPAL S, LATERRE PF, ABRAHAN E et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Grit. Care Med. (2004) 32(2):332–341.
  • GUNTHER A, WALMRATH D, GRIMMINGER F, WERNER A: Pathophysiology of acute lung injury. In: Seminars in Respiratory and Grit. Care Med. Hall JB and Schmidt GA (Eds.), Thieme Medical Publishers (2001) 22(3):247–258.
  • ZIMMERMAN JL, DELLINGER RP, STRAUBE RC, LEVIN JL: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Grit. Care Med. (2000) 28(9):3149–3154.
  • •This Phase I trial of TP-10 demonstrated in vivo activity and a good safety profile.
  • RIOUX P: TP-10 (AVANT Immunotherapeutics). Curr. Opia Investig. Drugs. (2001) 2(3):364–371.
  • SPRUNG CL, CARALIS PV, MARCIAL EH et al.: The effects of high- dose corticosteroids in patients with septic shock. N Engl. J. Med. (1984) 311(18):1137–1143.
  • BERNARD GR, LUCE JM, SPRUNG CL et al.: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. (1987) 317:1565–1570.
  • MEDURI GU, HEADLEY AS, GOLDEN E: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. "AMA (1998) 280:159–165.
  • ••This small trial reports a survival benefitfor unresolving ALT patients treated with corticosteroids, prompting a larger multi-centre controlled study to determine the efficacy and safety of corticosteroids in ALT.
  • ABRAHAM E, PARK YC, CONINGTON P et al: Liposomal prostaglandin El in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Grit. Care Med. (1996) 24(1):10–15.
  • ABRAHAM E, BAUGHMAN T, FLETCHER E et al.: Liposomal prostaglandin El (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Grit. Care Med. (1999) 27(8):1478–1485.
  • VINCENT JL, BRASE R, SANTMAN F et al: A multicentre, double-blind, placebo-controlled study of liposomal prostaglandin El (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. (2001) 27(10):1578–1583.
  • WALMRATH D, SCHNEIDER T, PILCH J, GRIMMINGER F, SEEGER W: Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet (1993) 342(8877):961–962.
  • VAN HEERDEN PV, BARDEN A, MICHALOPOULOS N, BULSARA MK, ROBERTS BL: Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest (2000) 117(3):819–827.
  • •This article reports a dose-ranging prospective trial of aerosolised prostacyclin In nine patients with severe ALT.
  • DOMENIGHETTI G, STRICKER H, WALDISPUEHL B: Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Grit. Care Med. (2001) 29(1):57–62.
  • GATTINONI L, PELOSI P, VITALE G et al.: Body position changes redistribute lung computed topographic density in patients with acute respiratory failure. Arieaesthesiology (1991) 74:15–23.
  • BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. J. Med. (2001)344:699–709.
  • DHAINAUT JF, LATERREPF, JANES JM et al.: Drotecogin alfa (activated) in the treatment of severe sepsis patients with multi-organ dysfunction: data from the PROWESS trial. Intensive Care Med. (2003)29(6)894–903.
  • VINCENT JL, ANGUS DC, ARTIGAS A et al.: Effects of drotecogin alfa (activated) on organ dysfunction in the PROWESS trial. Grit. Care Med. (2003) 31(3):834–40.
  • WARREN BL, EID A, SINGER P et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 286(15):1869–78.
  • CARRAWAY MS, WELTY-WOLF KE, MILLER DL et al: Blockade of tissue factor: treatment for organ injury in established sepsis. Am. J. Respir: Crit. Care Med. (2003) 167(9):1200–9.
  • ABRAHAM E, REINHART K, OPALS et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 290(2)238–47.
  • IQBAL 0, MAHMUT T, HOPPENSTEADT D et al.: Antithrombotic agents in the management of sepsis. Turk. J. Haem. (2002) 19(3):349–389.
  • LEWIS JF, JOBE AH: Surfactant and the adult respiratory distress syndrome. Am. Respir: Dis. (1993) 147:218–233.
  • HOLM BA, MATALON S: Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome. Ariesth. Arialg. (1989) 69:805–818.
  • PISON U, OBERTAKE U, BRAND M et al.: Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J. Trauma (1990) 30:19–26.
  • GREGORY TJ, LONGMORE WJ, MOXLEY MA et al: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin Invest. (1991) 99:1976–1981.
  • HAITSMA JJ, PAPADAKOS PJ, LACHMANN B: Surfactant therapy for acute lung injury/acute respiratory distress syndrome. Curr. Opin. Grit. Care (2004) 10:18–22.
  • EISNER MD, PARSONS P, MATTHAY MA, WARE L,GREENE K: Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax (2003) 58(11):983–988.
  • SPRAGG RG, LEWIS JF, WURST W et al.: Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am. I Respir. Grit. Care Med. (2003) 167(11):1562–6.
  • LEWIS JF: Surfactant - Where are we in 2003? Can. Resp J. (2003) 11(3):204–206.
  • KESECIOGLU JM, SCHULTZ MJ, LUNDBERG D, LAUVEN PM, LACHMANN B: Treatment of ALI/ARDS with surfactant. Am. I Respir. Crit. Care Med. (2001) 163(5):A819 (Asbtract).
  • ANZUETO A, BAUGHMAN RP, GUNTUPALLI KK et al.: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N. Engl. J. Med. (1996) 334:1417–1422.
  • WISWELL TE, SMITH RM, KATZ LB et al.: Bronchopulmonary segmental lavage with Surfaxin (KL (4)-surfactant) for acute respiratory distress syndrome. Am. J. Respir: Crit. Care Med. (1999) 160(01188–1195.
  • SPRAGG RG, LEWIS JF, WALMRATH HD et al.: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl. I Med. (2004) 351:884–892.
  • •This article showed no change in mortality with the use of surfactant in ALT, but suggested that direct forms of ALT may be more amenable to surfactant therapies.
  • BHATIA M AND MOO CHHALA S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. Path. (2004) 202:145–156.
  • VOERMAN HJ, VAN SCHIJNDEL RJ, GROENEVELD AB et al.: Effects of recombinant human growth hormone in patients with severe sepsis. Ann. Surg. (1992) 216(6):648–55.
  • TAKALA J, RUOKONEN E, WEBSTER NR et al.: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl. J. Med. (1999) 341(10:785–792.
  • LIU Z, YU Y, JIANG Y, LI J: Growth hormone increases circulating neutrophil activation and provokes lung microvascular injury in septic peritonitis rats. J. Surg. Res. (2002) 105(2):195–199.
  • AZOULAY E, ATTALAH H, YANG K et al.: Exacerbation by granulocyte colony-stimulating factor of prior acute lung injury: implication of neutrophils. Crit. Care Med. (2002) 30(9):2115–2122.
  • ATTALAH HL, AZOULAY E, YANG K et al.: Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Grit. Care Med. (2002) 30(9):2107–14.
  • AZOULAY E, ATTALAH H, HERIGAULT S et al.: Exacerbation with granulocyte colony-stimulating factor of prior acute lung injury during neutropenia recovery in rats. Crit. Care Med. (2003) 31(1)1157–L165.
  • ROOT RK, LODATO RF, PATRICK W et al: Multicenter, double-blind, placebo-controlled study of the use of filgastrim in patients hospitalized with pneumonia and severe sepsis. Grit. Care Med. (2003) 31:367–373.
  • WUNDERINK RG, LEEPER KV, SCHEIN R et al: Filgastrim in patients with pneumonia and severe sepsis or septic shock. Chest (2001) 119:523–529.
  • TANAKA H, NISHINO M, NAKAMORI Y et al.: Granulocyte colony-stimulating factor stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J. Trauma (2001) 51:1110–1116.
  • PRESNEILL JJ, HARRIS T, STEWART AG, CADE JF, WILSON JW: A randomized Phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. I Respir: Crit. Care Med. (2002) 166:138–143.
  • ••GM-CSF therapy did not worsen ALT ororgan dysfunction in patients with sepsis-related pulmonary dysfunction.
  • MATUTE-BELLO G, LILES WC, RADELLA F et al: Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/ macrophage colony-stimulating factor643 during the course of acute respiratory distress syndrome. Crit. Care Med. (2000) 28(1):1–7.
  • •This study found that GM-CSF in air spaces is associated with improved survival in ALT patients.
  • PELAEZ A, BECHARA RI, JOSHI PC, BROWN LAS, GUIDOT DM: Granulocyte/macrophage colony-stimulating factor treatment improves alveolar epithelial barrier function in alcoholic rat lung. Am. I Physiol. Lung Cell Mol. Physiol. (2004) 286(1)1106–L111.
  • ••This study revealed that GM-CSFtreatment promotes alveolar epithelial barrier integrity, particularly in chronic alcohol abuse, and may be relevant in general ALT patients.
  • PAINE R, WILCOXEN SE, MORRIS SB et al.: Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am. I Patna]. (2003) 163(6):2397–406.
  • SUGAHARA K, RUBI JS, MASON RJ et al.: Keratinocyte growth factor increases mRNAs for SP-A and SP-B in adult rat alveolar type II cells in culture. Am. J. Physiol. (1995) 2691355–L350.
  • GUO J, YI ES, HAVILL AM et al: Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am. I Physiol. (Lung Cell Mol. Physiol) (1998) 259:L800–L805.
  • STERN JB, FIEROBE L, PAUGAM C et al.: Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients. Grit. Care Med. (2000) 28:2326–2333.
  • HART CM: Nitric oxide in adult lung disease. Chest (1999) 115(5):1407–1417.
  • DELLINGER RP, ZIMMERMAN JL, TAYLOR RW et al: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized Phase II trial. Grit. Care Med. (1998) 26:15–23.
  • •This article reports a multi-centre trial evaluating the safety and dose response of 'NO in ARDS, fmding a frequent oxygenation improvement related to iNO, but no difference in clinical outcomes.
  • LUNDIN S, MANG H, SMITHIES M, STENQVIST 0, FROSTELL C: Inhalation of nitric oxide in acute lung injury: results of European multicentre study. Intensive Care Med. (1999) 25:911–919.
  • TAYLOR, RW, ZIMMERMAN JL, DELLINGER, RP et al.: Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA (2004) 291:1603–1609.
  • •This article revealed that low-dose inhaled NO in patients with non-sepsis-induced ALT did not affect mortality or duration of ventilatory support.
  • TAANBE E, UEDA M, ENDO M, KIAJIMA M: Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide. Grit. Care Med. (1994) 22(11):1762–1768.
  • TANABE E, UEDA M, ENDO M, KITAJIMA M: The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. Am. I Respir. Grit. Care Med. (1996) 154(5):1351–1356.
  • MITAKA C, HIRATA Y, NAGURA T, TSUNODA Y, AMAHA K: Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest (1998) 114:223–228.
  • LEWIS CA, MARTIN GS: Understanding and managing fluid balance in patients with acute lung injury. Curl: Opin. Grit. Care (2004) 10(1):13–17.
  • MITCHELL JP, SCHULLER D, CALANDRINO FS, SCHUSTER DP: Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am. Rev. Respir. Dis. (1992) 145:990–998.
  • •Pulmonary oedema patients managed by fluid restriction and measures of extravascular lung water had reduced duration of mechanical ventilation.
  • MARTIN GS, MANGIALARDI RJ, WHEELER AP et al.: Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Grit. Care Med. (2002) 30(10):2175–2182.
  • MARTIN GS, MOSS M, WHEELER AP, BERNARD GR: The addition of albumin to furosemide therapy improves oxygenation in hypoproteinemic ALI. Am. Respir. Grit. Care Med. (2004) 169(7):A256.
  • QUINLAN GJ, MUMBY S, MARTIN GS et al: Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Grit. Care Med. (2004) 32(3):755–759.
  • •This study revealed that albumin administration in patients with ALT improves thiol-dependent antioxidant status.
  • CALDERWOOD HW, MODELL JH, RUIZ BC, BROGDON JE, HOOD CI: Pulmonary lavage with liquid fluorocarbon in a model of pulmonary edema. Anesthesiology (1973) 38:141–144.
  • MODELL JH, NEWBY EJ, RUIZ BC: Long-term survival of dogs after breathing oxygenated fluorocarbon liquid. Fed Proc. (1979) 29:1731–1736.
  • TUTUNCU AS, FAITHFUL NS, AKPIR K, LACHMANN B: Improvement of gas exchange dose dependently by intratracheal perfluorocarbon administration in adult animals with acute respiratory failure. Clin. Intensive Care (1992) 3(Suppl.):72.
  • RICHMANN PS, WOLFSON MR, SHAFFER TH: Lung lavage with oxygenated perfluorochemical liquid in acute lung injury. Grit. Care Med. (1993) 20:768–774.
  • NESTI FD, FUHRMAN BP, STEINHORN DM et al.: Perfluorocarbon-associated gas exchange in gastric aspiration. Grit. Care Med. (1994) 22(9):1445–1452.
  • HIRSCHL RB, TOOLEY R, PARENT A, JOHNSON K, BARTLET RH: Evaluation of gas exchange, pulmonary compliance, and lung injury during total and partial liquid ventilation in the acute respiratory distress syndrome. Grit. Care Med. (1996) 24(6):1001–1008.
  • LOWE C, SHAFFER T: Pulmonary vascular resistance in the fluorocarbon-filled lung. I Appl. Physiol. (1986) 60:154–159.
  • LANGE NR, KOZLOWSKI JK, GUST R, SHAPIRO SD, SCHUSTER DP: Effect of partial liquid ventilation on pulmonary vascular permeability and edema after experimental acute lung injury. Am. Respir. Grit. Care Med. (2000)162(1)271–277.
  • HIRSCHL RB, PRANIKOFF T, WISE C: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. IA/VIA (1996) 275:383–389.
  • HIRSCHL RB, CONRAD S, KAISER R et al: Partial liquid ventilation in adult patients with ARDS: a multicenter Phase I-II trial. Ann. Surg. (1998) 228(5)692–700.
  • HIRSCHL RB, CROCE M, GORED et al: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am. J. Respir Crit. Care Med. (2002) 165(6):781–787.
  • •This study did not find any significant differences in mortality or days off the ventilator in patients with ARDS treated with liquid ventilation.
  • KAISERS U, KELLY KP, BUSCH T: Liquid ventilation. BE Anaesth. (2003) 91(1):143–51.
  • DIDLAKE R, KIRCHNER KA, LEWIN J, BOWER HD, MARKAV A: Protection from ischemic renal injury by fructose-1,6-diphosphate infusion in the rat. Circulatory Shock (1985) 16(2):205–212.
  • WANG Y, FOLKESSON HG, JAYR C, WARE LB, MATTHAY MA: Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy. I Appl. Physic] (1999) 87(5):1852–1860.
  • McAULEY DF, FRANK JA, FANG X, MATTHAY MA: Clinically relevant concentrations of 02-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit. Care Med. (2004) 32(7):1470–1476.
  • ••This investigation showed that 02-adrenergic agonists in the airspace reduce pulmonary oedema in acid aspiration-induced lung injury.
  • STEINBERG S, DEHRING D, MARTIN D et al: Amelioration of pulmonary pathophysiology of adult respiratory distress syndrome by sulindac, a cyclo-oxygenase inhibitor. J. Trauma (1987) 67:1103–1110.
  • BERNARD G, WHEELER A, RUSSELL Jet al.: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl. J. Med. (1997) 336:912–918.
  • ARONS MM, WHEELER AP, BERNARD GR et al.: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Grit. Care Med. (1999) 27(4):699–707.
  • HAFNER D, IBRAHIM M, WOLLIN L, GERMANN PG: Cyclooxygenase-inhibition enhances the effects of rSP-C surfactant therapy in a rat lavage model of acute respiratory distress syndrome (ARDS). Exp. Toxicol Pathol (2003) 55(1):59–68.
  • GADEK JE, DEMICHELE SJ, KARLSTAD: Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Grit. Care Med. (1999) 27(8):1409–1420.
  • •This article reports reductions in pulmonary inflammation and a reduced duration of mechanical ventilation in ALT patients fed with an anti-oxidant enriched enteral feeding formula.
  • PACHT ER, DEMICHELE SJ, NELSON JL et al: Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein flux in patients with acute respiratory distress syndrome. Crit. Care Med. (2003) 31(2):491–500.

Websites

  • http://www.ono.co.jp/eng/cn/contents/sm_cn_061302.htm. Announcement of launch of Silvestat for treatment of ALT (2005).
  • http://www.avantimmune.com/news/ articles.html Complete references on complement inhibitors (2005).
  • http://www.ardsnet.org/lasrs.php Late Steroid Rescue Study (LaSRS): The efficacy of corticosteroids as rescue therapy for late phase of ARDS (2005).
  • http://www.leopharma.com/ 41256A84002BE7FC/0/ 59400A0E93DD0652C1256EAD007340 E5?OpenDocument Press release announcing the cessation of Phase III study of HL10 in ALT (2005).
  • http://www.discoverylabs.com/ 192004pr/ 120704-PR.pdf Press release of preliminary data from the Phase II trial of Surfaxin (2005).
  • http://www.ardsnet.org/factt.php The Fluid and Catheter Treatment Trial (FACTT) in ARDS (2005).
  • http://clinicaltrials.gov/show/ NCT00030121 Description of study of carperitide in ARDS (2005).
  • http://www.pslgroup.com/dg/D266.htm Information on the use of CPC-111 in patients after CABG and its effect on length of stay in ICU (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.